Literature DB >> 25395878

State Investments in Psychiatric Innovation: Investigating Unmeasured State Factors.

Marisa Elena Domino1, Christopher Alan Beadles2.   

Abstract

We apply three separate panel data estimation methods to examine the diffusion of technologies at the state-level. These methods include the Hausman-Taylor random effects model, the fixed effects vector decomposition (FEVD), and generalized estimating equations (GEE). We discuss the assumptions required of each and assess the stability of our policy results across the three models for a longitudinal study of the diffusion of newer psychotropic technologies. We find a reasonable level of consistency among marginal effects for time varying independent variables between our three estimation methods but some discrepancy in the estimated measure of precision in our empirical application. We find a number of policy conclusions are quite stable across estimation methods and may be of interest to state-level mental health policy decision makers.

Entities:  

Keywords:  Fixed effects; Innovation; Panel data; Random effects; State factors

Year:  2014        PMID: 25395878      PMCID: PMC4226516          DOI: 10.1007/s10742-014-0116-y

Source DB:  PubMed          Journal:  Health Serv Outcomes Res Methodol        ISSN: 1387-3741


  32 in total

1.  Medicaid prescription drug coverage: state efforts to control costs.

Authors:  Dawn M Gencarelli
Journal:  NHPF Issue Brief       Date:  2003-05-10

2.  Price elasticity and pharmaceutical selection: the influence of managed care.

Authors:  Marisa Elena Domino; David S Salkever
Journal:  Health Econ       Date:  2003-07       Impact factor: 3.046

3.  Regional variation and clinical indicators of antipsychotic use in residential treatment: a four-state comparison.

Authors:  Purva H Rawal; John S Lyons; James C MacIntyre; John C Hunter
Journal:  J Behav Health Serv Res       Date:  2004 Apr-Jun       Impact factor: 1.505

Review 4.  Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.

Authors:  Alicia Ruelaz Maher; Margaret Maglione; Steven Bagley; Marika Suttorp; Jian-Hui Hu; Brett Ewing; Zhen Wang; Martha Timmer; David Sultzer; Paul G Shekelle
Journal:  JAMA       Date:  2011-09-28       Impact factor: 56.272

5.  Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system.

Authors:  Marcia Valenstein; John F McCarthy; Rosalinda V Ignacio; Gregory W Dalack; Thomas Stavenger; Frederic C Blow
Journal:  Psychiatr Serv       Date:  2006-01       Impact factor: 3.084

6.  Hybrid Corn and the Economics of Innovation.

Authors:  Z Griliches
Journal:  Science       Date:  1960-07-29       Impact factor: 47.728

7.  Who are the new users of antipsychotic medications?

Authors:  Marisa Elena Domino; Marvin S Swartz
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

8.  How a managed behavioral health care carve-out plan affected spending for episodes of treatment.

Authors:  H A Huskamp
Journal:  Psychiatr Serv       Date:  1998-12       Impact factor: 3.084

9.  Cost shifting in a mental health carve-out for the AFDC population.

Authors:  E C Norton; R C Lindrooth; B Dickey
Journal:  Health Care Financ Rev       Date:  1997

10.  Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Authors:  Robert A Rosenheck; Douglas L Leslie; Jody Sindelar; Edward A Miller; Haiqun Lin; T Scott Stroup; Joseph McEvoy; Sonia M Davis; Richard S E Keefe; Marvin Swartz; Diana O Perkins; John K Hsiao; Jeffrey Lieberman
Journal:  Am J Psychiatry       Date:  2006-12       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.